Related Experiment Video

Updated: May 26, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

EGFR-mediated G1/S transition contributes to the multidrug resistance in breast cancer cells

Shu-Jun Chen1, Jing Luan, Hai-Shi Zhang

  • 1Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, 200040, China.

Molecular Biology Reports
|December 20, 2011
PubMed

Insights

Multidrug resistance (MDR) in breast cancer is linked to cell cycle phase. Epidermal growth factor receptor (EGFR) drives MDR by promoting cell cycle progression, offering new therapeutic targets.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Medicine

Background:

  • Multidrug resistance (MDR) remains a significant challenge in effective cancer chemotherapy.
  • Recurrent cancers often exhibit refractoriness to subsequent treatments, necessitating understanding of resistance mechanisms.

Purpose of the Study:

  • To investigate the role of epidermal growth factor receptor (EGFR) in phase-specific chemotherapy resistance in human breast cancer cells.
  • To elucidate the molecular mechanisms underlying EGFR-mediated MDR, focusing on cell cycle regulation.

Main Methods:

  • Induction of G1 and S phase arrest using thymidine in breast cancer cell cultures.
  • Manipulation of EGFR expression (overexpression and depletion) and assessment of chemosensitivity.
  • Analysis of CyclinD1 expression and its role in EGFR-mediated MDR using RNA interference.

Main Results:

  • G1-arrested cells displayed increased chemosensitivity, while S-phase arrested cells showed enhanced resistance.
  • EGFR overexpression promoted MDR phenotypes by accelerating the G1/S phase transition; EGFR depletion reversed this effect.
  • EGFR upregulated CyclinD1 expression, and targeting CyclinD1 diminished EGFR-induced MDR.

Conclusions:

  • EGFR plays a critical role in mediating phase-specific chemotherapy resistance in breast cancer.
  • The EGFR-CyclinD1 axis is a key pathway through which breast cancer cells evade chemotherapy.
  • Targeting the EGFR-CyclinD1 pathway may offer novel therapeutic strategies against MDR breast cancer.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.